Company name: Joint Venture (Tetra Bio-Pharma and Altus Formulation)
Description: Developer of a series of cannabinoid-receptor targeted therapeutics addressing multiple areas of high unmet need.
Industry: Healthcare | Group: | Code:
Start up capital raised (USD Million):
Ownership: Privately Held (no backing)
Revenue (USD Million):
Gross profit (USD Million):
Net income (USD Million)
Earnings before interest, tax, depreciation and amortization (EBITDA):
Financing Status: Tetra Bio-Pharma (TSX VENTURE: TBP) (OTCQB: TBPMF) and Altus Formulation Inc. have entered into an agreement to form a joint venture as of April 29, 2019. The joint venture will work to develop a series of cannabinoid-receptor targeted therapeutics addressing multiple areas of high unmet need.
Number of active investors:
Profile last updated: 03-May-2019
Last known valuation:
Last known valuation date: